Document:

Exhibit 10.1 

BB&T CORPORATION

2012 INCENTIVE PLAN

Restricted Stock Unit Agreement 

(Non-Employee Directors)

	Grant Date:	________________
	Date Vested (Subject to Section 3):	________________

THIS AGREEMENT
(the “Agreement”), made effective as of February 24, 2015 (the “Grant Date”), between BB&T
CORPORATION, a North Carolina corporation (“BB&T”) for itself and its Affiliates, and the Non-Employee Director
(the “Participant”) specified in the above Notice of Grant and Agreement (the “Notice of Grant”),
is made pursuant to and subject to the provisions of the BB&T Corporation 2012 Incentive Plan, as it may be amended and/or
restated from time to time (the “Plan”).

RECITALS:

BB&T desires
to carry out the purposes of the Plan by affording the Participant an opportunity to acquire shares of BB&T Common Stock, $5.00
par value per share (the “Common Stock”), as hereinafter provided.

In consideration
of the foregoing, of the mutual promises set forth below and of other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows:

1.                 
Incorporation of Plan. The rights and duties of BB&T and the Participant under this Agreement shall in all
respects be subject to and governed by the provisions of the Plan, the terms of which are incorporated herein by reference. In
the event of any conflict between the provisions in this Agreement and those of the Plan, the provisions of the Plan shall govern.
Unless otherwise provided herein, capitalized terms in this Agreement shall have the same definitions as set forth in the Plan.

2.                 
Grant of Restricted Stock Unit. Subject to the terms of this Agreement and the Plan, BB&T hereby grants the
Participant a Restricted Stock Unit (the “Award”) for the number of whole shares of Common Stock (the “Shares”)
specified in the Notice of Grant. The “Restriction Period” is the period beginning on the Grant Date and ending
on such date or dates, and satisfaction of such conditions, as described in Section 3 and Section 4 herein. For the purposes herein,
the Shares subject to the Award are units that will be reflected in a book account maintained by BB&T and that will be settled
in whole shares of Common Stock, if and to the extent permitted pursuant to this Agreement and the Plan. Prior to distribution
of the Shares upon vesting of the Award, the Award shall represent an unsecured obligation of BB&T, payable (if at all) only
from BB&T’s general assets.

3.                 
Vesting of Award. Subject to the terms of the Plan and this Agreement (including but not limited to the provisions
of Section 4 and Section 5 herein), the Award shall become fully

    	 

    	 

    

vested and earned on December 31, 2015.
The Administrator has sole authority to determine whether and to what degree the Award has vested and is payable, and to interpret
the terms and conditions of this Agreement and the Plan.

4.                 
Termination of Service; Forfeiture of Award; Effect of Change of Control.

(a)              
Except as may be otherwise provided in the Plan or Section 4(b) of this Agreement, in the event that the service of
the Participant as a Director terminates for any reason and the Award has not vested pursuant to Section 3, then the Award, to
the extent not vested as of the Participant’s termination of service date, shall be forfeited immediately upon such termination
of service, and the Participant shall have no further rights with respect to the Award or the Shares underlying the Award. The
Administrator (or its designee, to the extent permitted under the Plan) shall have sole discretion to determine if a Participant’s
rights have terminated pursuant to the Plan and this Agreement, including but not limited to the authority to determine the basis
for the Participant’s termination of service. The Participant expressly acknowledges and agrees that, except as otherwise
provided herein, the termination of the Participant’s service as a Director shall result in forfeiture of the Award and the
underlying Shares to the extent the Award has not vested as of the Participant’s termination of service date. As used in
this Agreement, the phrase “termination of service” means a “separation from service,” within the meaning
of Section 409A, as a Director.

(b)              
Notwithstanding the provisions of Section 3 and Section 4(a), the following provisions shall apply if any of the following
shall occur prior to December 31, 2015:

		(i)	Death. In the event that the Participant remains in the continuous service of BB&T or
an Affiliate as a Director from the Grant Date until the Participant’s death, the Award shall become fully vested as of the
date of death without regard to the vesting schedule set forth in Section 3 herein.

		(ii)	Disability. In the event that the Participant remains in the continuous service of BB&T
or an Affiliate as a Director from the Grant Date until the date of the Participant’s disability (as determined by the Administrator
or its designee in accordance with the Plan and, if applicable, Section 409A), the Award shall become fully vested as of the Participant’s
date of termination of service as a Director on account of disability without regard to the vesting schedule set forth in Section
3 herein.

		(iii)	Change of Control.

		(A)	In the event that there is “Change of Control,” as defined in Section 4(b)(iii)(B),
of BB&T subsequent to the date hereof, the Award shall be payable in accordance with this Agreement and become fully vested
as of the effective date of such event without regard to the vesting schedule set forth in Section 3 herein.

    	- 2 -

    	 

    

		(B)	For purposes of this Section 4(b)(iii), a “Change of Control” will be deemed
to have occurred on the earliest of the following dates: (i) the date any person or group of persons (as defined in Section 13(d)
and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), together with its affiliates,
excluding employee benefit plans of BB&T and its Affiliates, is or becomes, directly or indirectly, the “beneficial owner”
(as defined in Rule 13d-3 promulgated under the Exchange Act) of securities of BB&T representing thirty percent (30%) or more
of the combined voting power of BB&T’s then outstanding securities; or (ii) the date when, as a result of a tender offer
or exchange offer for the purchase of securities of BB&T (other than such an offer by BB&T for its own securities), or
as a result of a proxy contest, merger, consolidation or sale of assets, or as a result of any combination of the foregoing, individuals
who at the beginning of any consecutive twelve- (12-) month period during the Restriction Period of the Award constituted BB&T’s
Board, plus new directors whose election or nomination for election by BB&T’s shareholders is approved by a vote of at
least two-thirds of the directors still in office who were directors at the beginning of such twelve- (12-) month period (collectively,
the “Continuing Directors”), cease for any reason during such twelve- (12-) month period to constitute at least
two-thirds of the members of such board of directors; (iii) the date the shareholders of BB&T approve an agreement for the
sale or disposition by BB&T of all or substantially all of BB&T’s assets within the meaning of Section 409A; or (iv)
the date that any one person, or more than one person acting as a group, acquires ownership of stock of BB&T that, together
with stock held by such person or group constitutes more than fifty percent (50%) of the total fair market value or total voting
power of the stock of BB&T within the meaning of Section 409A.

5.                 
Settlement of Award and Distribution of Shares.

(a)              
Upon vesting, the Award shall be payable in a lump sum in whole shares of Common Stock. Fractional Shares shall not
be issuable hereunder, and unless the Administrator determines otherwise, any such fractional Share shall be disregarded.

(b)              
Shares of Common Stock subject to the Award shall, upon vesting of the Award, be issued and distributed to the Participant
(or, if the Participant is deceased, to the Participant’s beneficiary or beneficiaries) in a lump sum within ninety (90)
calendar days after the end of the Restriction Period (provided that if such ninety- (90-) day period begins in one calendar

    	- 3 -

    	 

    

year and ends in another, the Participant
(or the Participant’s beneficiary or beneficiaries) shall not have the right to designate the calendar year of payment).

6.                 
No Right to Continued Service. Neither the Plan, the grant of the Award, nor any other action related to the
Plan shall confer upon the Participant any right to continue in the service of BB&T or an Affiliate as a Director or in any
other capacity or affect in any way with the right of BB&T or an Affiliate to terminate the Participant’s service at
any time. Except as otherwise expressly provided in the Plan or this Agreement or as determined by the Administrator, all rights
of the Participant with respect to the Award shall terminate upon termination of the service of the Participant with BB&T or
an Affiliate. The grant of the Award does not create any obligation on the part of BB&T to grant any further Awards.

7.                 
Nontransferability of Award and Shares. The Award shall not be transferable (including by sale, assignment, pledge
or hypothecation) other than by will or the laws of intestate succession. The designation of a beneficiary in accordance with Plan
procedures does not constitute a transfer; provided, however, that unless disclaimer provisions are specifically included in a
beneficiary designation form accepted by the Administrator, no beneficiary of the Participant may disclaim the Award. The Participant
shall not sell, transfer, assign, pledge or otherwise encumber the Shares subject to the Award until the Restriction Period has
expired and all conditions to vesting and distribution have been met.

8.                 
Superseding Agreement; Binding Effect. This Agreement supersedes any statements, representations or agreements
of BB&T with respect to the grant of the Award or any related rights, and the Participant hereby waives any rights or claims
related to any such statements, representations or agreements. This Agreement does not supersede or amend any existing confidentiality
agreement, nonsolicitation agreement, noncompetition agreement, service agreement, or any other similar agreement between the Participant
and BB&T or an Affiliate, including, but not limited to, any restrictive covenants contained in such agreements.

9.                 
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of
North Carolina, without regard to the principles of conflicts of law, and in accordance with applicable United States federal laws.

10.             
Amendment and Termination; Waiver. Subject to the terms of the Plan, this Agreement may be amended or terminated
only by the written agreement of the parties hereto. The waiver by BB&T of a breach of any provision of this Agreement by the
Participant shall not operate or be construed as a waiver of any subsequent breach by the Participant. Notwithstanding the foregoing,
the Administrator shall have unilateral authority to amend the Plan and this Agreement (without Participant consent) to the extent
necessary to comply with applicable law or changes to applicable law (including but in no way limited to Section 409A and federal
securities laws), and the Participant hereby consents to any such amendments to the Plan and this Agreement.

11.             
Issuance of Shares; Rights as Shareholder. The Participant and the Participant’s legal representatives,
legatees or distributees shall not be deemed to be the holder of any Shares subject to the Award and shall not have any voting
rights, dividend rights or other rights of a shareholder unless and until such Shares have been issued to the Participant or them.
No Shares

    	- 4 -

    	 

    

subject to the Award shall be issued
at the time of grant of the Award. Shares subject to the Award shall be issued in the name of the Participant (or, if the Participant
is deceased, in the name of the Participant’s beneficiary or beneficiaries) as soon as practicable after, and only to the
extent that, the Award has vested and if such distribution is otherwise permitted under the terms of Section 5 herein. Neither
dividends nor dividend equivalent rights shall be granted in connection with the Award, and the Award shall not be adjusted to
reflect the distribution of any dividends on the Common Stock (except as may be otherwise provided under the Plan). No dividends
on the Shares shall be payable prior to both (i) the vesting of the Award and (ii) the issuance and distribution of Shares to the
Participant.

12.             
Withholding; Tax Matters; Fees.

(a)              
BB&T shall report all income and prior to the delivery or transfer of Shares or any other benefit conferred under
the Plan, BB&T or its agent shall withhold all required local, state, federal, foreign and other income tax obligations and
any other amount required to be withheld by any governmental authority or law and paid over by BB&T to such authority for the
account of such recipient. In accordance with procedures established by the Administrator, the Participant may arrange to pay all
applicable taxes in cash. In the event the Participant does not make such arrangements, such tax obligations shall be satisfied
by the withholding of Shares to which the Participant is entitled. The number of Shares to be withheld shall have a Fair Market
Value as of the date that the amount of tax to be withheld is determined as nearly equal as possible to the amount of such obligations
being satisfied.

(b)              
BB&T has made no warranties or representations to the Participant with respect to the tax consequences (including
but not limited to income tax consequences) related to the Award or issuance, transfer or disposition of Shares (or any other benefit)
pursuant to the Award, and the Participant is in no manner relying on BB&T or its representatives for an assessment of such
tax consequences. The Participant acknowledges that there may be adverse tax consequences with respect to the Award (including
but not limited to the acquisition or disposition of the Shares subject to the Award) and that the Participant should consult a
tax advisor prior to such acquisition or disposition. The Participant acknowledges that the Participant has been advised that the
Participant should consult with the Participant’s own attorney, accountant, and/or tax advisor regarding the decision to
enter into this Agreement and the consequences thereof. The Participant also acknowledges that BB&T has no responsibility to
take or refrain from taking any actions in order to achieve a certain tax result for the Participant.

(c)               
All third party fees relating to the release, delivery, or transfer of any Award or Shares shall be paid by the Participant
or other recipient. To the extent the Participant or other recipient is entitled to any cash payment from BB&T or any of its
Affiliates, the Participant hereby authorizes the deduction of such fees from such payment(s) without further action or authorization
of the Participant or other recipient; and to the extent the Participant or other recipient is not entitled to any such payments,
the Participant or other recipient shall pay BB&T or its designee an amount equal to such fees immediately upon the third party’s
charge of such fees.

13.             
Administration. The authority to construe and interpret this Agreement and the Plan, and to administer all aspects
of the Plan, shall be vested in the Administrator, and the Administrator shall have all powers with respect to this Agreement as
are provided in the Plan.

    	- 5 -

    	 

    

Any interpretation of this Agreement
by the Administrator and any decision made by it with respect to this Agreement is final and binding on the parties hereto.

14.             
Notices. Any and all notices under this Agreement shall be in writing and sent by hand delivery or by certified
or registered mail (return receipt requested and first-class postage prepaid), in the case of BB&T, to its Human Systems Division,
200 West Second Street (27101), PO Box 1215, Winston-Salem, NC 27102, attention: Human Systems Division Manager, and in the case
of the Participant, to the last known address of the Participant as reflected in BB&T’s records.

15.             
Severability. The provisions of this Agreement are severable, and if any one or more provisions may be determined
to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

16.             
Compliance with Laws; Restrictions on Award and Shares. BB&T may impose such restrictions on the Award and
the Shares or other benefits underlying the Award as it may deem advisable, including without limitation restrictions under the
federal securities laws, federal tax laws, the requirements of any stock exchange or similar organization and any blue sky, state
or foreign securities laws applicable to such Award or Shares. Notwithstanding any other provision in the Plan or this Agreement
to the contrary, BB&T shall not be obligated to issue, deliver or transfer any shares of Common Stock, make any other distribution
of benefits under the Plan, or take any other action, unless such delivery, distribution or action is in compliance with all applicable
laws, rules and regulations (including but not limited to the requirements of the Securities Act). BB&T may cause a restrictive
legend or legends to be placed on any Shares issued pursuant to the Award in such form as may be prescribed from time to time by
applicable laws and regulations or as may be advised by legal counsel.

17.             
Successors and Assigns. Subject to the limitations stated herein and in the Plan, this Agreement shall be binding
upon and inure to the benefit of the Participant and the Participant’s executors, administrators and permitted transferees
and beneficiaries and BB&T and its successors and assigns.

18.             
Counterparts; Further Instruments. This Agreement may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. The parties hereto agree to
execute such further instruments and to take such further action as may be reasonably necessary to carry out the purposes and intent
of this Agreement.

19.             
Right of Offset. Notwithstanding any other provision of the Plan or this Agreement, subject to any applicable
laws to the contrary, BB&T may reduce the amount of any benefit or payment otherwise payable to or on behalf of the Participant
by the amount of any obligation of the Participant to BB&T or an Affiliate that is or becomes due and payable, and the Participant
shall be deemed to have consented to such reduction; provided, however, that to the extent Section 409A is applicable, such offset
shall not exceed the greater of Five Thousand Dollars ($5,000) or the maximum offset amount then permitted under Section 409A.

    	- 6 -

    	 

    

20.             
Adjustment of Award. The Administrator shall have authority to make adjustments to the terms and conditions of
the Award in recognition of unusual or nonrecurring events affecting BB&T or any Affiliate, or the financial statements of
BB&T or any Affiliate, or of changes in applicable laws, regulations or accounting principles, if the Administrator determines
that such adjustments are appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended
to be made available under the Plan or necessary or appropriate to comply with applicable laws, rules or regulations.

IN WITNESS WHEREOF, BB&T and
the Participant have entered into this Agreement effective as of the Grant Date. Should the Participant fail to acknowledge his
or her electronic acceptance of this Agreement, this Agreement may become null and void as of the Grant Date and the Participant
may forfeit any and all rights hereunder at the discretion of the Administrator.EXHIBIT 10.1

INDEPENDENT DIRECTOR AGREEMENT

 

THIS INDEPENDENT DIRECTOR AGREEMENT (this “Agreement”) is made and entered into this ___ day of April, 2015, by and between CELLCEUTIX CORPORATION, a Nevada corporation (the “Company”) and ____________________________________________, an individual residing at ____________________________________________ (the “Director”).

 

RECITALS:

 

WHEREAS, the Company desires to appoint the Director to serve on the Company’s board of directors (the “Board”) and the Director desires to accept such appointment to serve on the Board; and

 

WHEREAS, the Director may be appointed as a member of one or more committees of the Board; and

 

WHEREAS, the Director may also be appointed to serve as Chairman of one or more committees of the Board.

 

AGREEMENT:

 

NOW, THEREFORE, in consideration of the foregoing and the Director’s services to the Company as a member of the Board, as a member of such Committees of the Board to which he may be appointed from time to time and as Chairman of one or more committees to which he may be appointed in such capacity from time to time, and intending to be legally bound hereby, the Company and the Director hereby agree as follows:

 

1.  Term. The Company hereby appoints the Director, and the Director hereby accepts such appointment by the Company, for the purposes and upon the terms and conditions contained in this Agreement. The term of such appointment shall commence upon April ___, 2015 (the “Commencement Date”) and shall expire one (1) year from the Commencement Date (the “Expiration Date”), unless terminated prior to the Expiration Date pursuant to the Director’s earlier resignation or removal from office in accordance with the Company’s then current Articles of Incorporation, as may be amended from time to time. In the event that the Director’s successor has not been elected and qualified as of the Expiration Date, the Director shall continue to serve hereunder until such successor has been duly elected and qualified. 

 

2.  Compensation. In exchange for the Director’s service as (a) a member of the Board, (b) a member of each committee of the Board to which he may be appointed, and (c) Chairman of each committee of the Board to which he may be appointed, the Company agrees to compensate the Director, and the Director agrees to accept the following compensation, subject to the terms herein:

 

(i) an annual cash compensation fee (“Annual Fee”) in an aggregate amount of $25,000, which Annual Fee shall be paid to the Director, pro rata, on the last day of each fiscal quarter commencing on June 30, 2015;

 

	 
	
1

	

 

(ii) 20,000 shares of the Company’s Class A Common Stock, par value $0.0001 per share (“Common Stock”), which shares shall be restricted when issued and shall vest and be issued immediately upon the Company successfully listing the Common Stock on The Nasdaq Capital Market; and

 

(iii) A five year option, (the “Option”), with a black scholes valuation equal to $20,000 on the issuance date, to purchase shares of Common Stock of the Company, at a per share price equal to the the closing price of the stock one trading day prior to the date of issuance, which option shall vest in full on the Expiration Date.

 

In the event that the Director serves less than a full year on the Board, the Company shall only be obligated to pay the pro rata portion of such Annual Fee to the Director for his services performed during such year. Furthermore, the vesting of the Option shall not accelerate in the event the Director serves less than a full year on the Board.

 

3.  Independence. The Director acknowledges that his appointment hereunder is contingent upon the Board’s determination that he is “independent” with respect to the Company, as such term is defined by Section 5605 of the Nasdaq Stock Market’s Listing Rules, and that his appointment may be terminated by the Company in the event that the Director does not maintain such independence.

 

4.  Duties. The Director shall exercise his powers in good faith and in the best interests of the Company, including but not limited to, the following: 

 

(a) Conflicts of Interest. In the event that the Director has a direct or indirect financial or personal interest in a contract or transaction to which the company is a party, or the Director is contemplating entering into a transaction that involves use of corporate assets or competition against the Company, the Director shall promptly disclose such potential conflict to the applicable Board committee and proceed as directed by such committee or the Board, as applicable.

 

(b) Corporate Opportunities. Whenever the Director becomes aware of a business opportunity, related to the Company’s business, which one could reasonably expect the Director to make available to the Company, the Director shall promptly disclose such opportunity to the applicable Board committee and proceed as directed by such committee.

 

(c) Confidentiality. The Director agrees and acknowledges that, by reason of the nature of his duties as Director, he will have or may have access to and become informed of proprietary, confidential and secret information which is a competitive asset of the Company (“Confidential Information”), including, without limitation, any lists of customers or suppliers, distributors, financial statistics, research data or any other statistics and plans or operation plans or other trade secrets of the Company and any of the foregoing which belong to any person or company but to which the Director has had access by reason of his relationship with the Company. The term “Confidential Information” shall not include information which: (i) is or becomes generally available to the public other than as a result of a disclosure by the Director or his representatives; or (ii) is required to be disclosed by the Director due to governmental regulatory or judicial process. The Director agrees faithfully to keep in strict confidence, and not, either directly or indirectly, to make known, divulge, reveal, furnish, make available or use (except for use in the regular course of his employment duties) any such Confidential Information. The Director acknowledges that all manuals, instruction books, price lists, information and records and other information and aids relating to the Company’s business, and any and all other documents containing Confidential Information furnished to the Director by the Company or otherwise acquired or developed by the Director, shall at all times be the property of the Company. Upon termination of the Director’s services hereunder, the Director shall return to the Company any such property or documents which are in his possession, custody or control, but his obligation of confidentiality shall survive such termination until and unless any such Confidential Information shall have become, through no fault of the Director, generally known to the public. The obligations of the Director under this subsection are in addition to, and not in limitation or preemption of, all other obligations of confidentiality which the Director may have to the Company under general legal or equitable principles.

 

	 
	
2

	

 

(d) Non-competition and Non-soliciation. The Director agrees that commencing on the Commencement Date and for a period of one year after the Expiration Date, the Director will not, either individually or as owner, partner, agent, employee, or consultant, engage in any activity that involves the development of drugs with compounds that are similar to the compounds used by the Company in its trials and drug development, and will not on his own behalf, or on behalf of any third party, directly or indirectly hire, discuss employment with, or recommend to any third party the employment of any employee of the Company or any of its affiliates who was actively employed by the Company or an affiliate during the term of this Agreement without regard to whether that employee has subsequently terminated his or her employment with the Company. The Director may continue to engage in any drug development activities and clinical trials for third parties so long as such activities exclude the dissemination or disclosure of the Company’s Confidential Information. If at any time during the term of this Agreement there is doubt as to whether the Director’s professional activities comport with the terms of this Section 4(d), the Director must obtain consent from the Company in order to engage in the relevant activity, which consent will not be unreasonably withheld.

 

5.  Expenses. Upon submission of adequate documentation by the Director to the Company, the Director shall be reimbursed for all reasonable expenses incurred by him in connection with his positions as a member of the Board and for his services as a member of each committee of the Board to which he may be appointed.

 

6.  Withholding. The Director agrees to cooperate with the Company to take all steps necessary or appropriate for the withholding of taxes by the Company required under law or regulation in connection herewith, and the Company may act unilaterally in order to comply with such laws.

 

7.  Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Company and its successors and assigns.

 

8.  Recitals. The recitals to this Agreement are true and correct and are incorporated herein, in their entirety, by this reference.

 

9.  Validity. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.

 

10. Headings and Captions. The titles and captions of paragraphs and subparagraphs contained in this Agreement are provided for convenience of reference only, and shall not be considered terms or conditions of this Agreement.

 

11. Neutral Construction. Neither party hereto may rely on any drafts of this Agreement in any interpretation of the Agreement. Both parties to this Agreement have reviewed this Agreement and have participated in its drafting and, accordingly, neither party shall attempt to invoke the normal rule of construction to the effect that ambiguities are to be resolved against the drafting party in any interpretation of this Agreement.

 

12. Counterparts. This Agreement may be executed in one (1) or more counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.

 

13. Miscellaneous. This Agreement shall be construed under the laws of the State of Nevada, without application to the principles of conflicts of laws. This Agreement constitutes the entire understanding between the parties with respect to its subject matter, and there are no prior or contemporaneous written or oral agreements, understandings, or representations, express or implied, directly or indirectly related to this Agreement that are not set forth or referenced herein. This Agreement supersedes all negotiations, preliminary agreements, and all prior and contemporaneous discussions and understandings of the parties hereto and/or their affiliates. The Director acknowledges that he has not relied on any prior or contemporaneous discussions or understandings in entering into this Agreement. The terms and provisions of this Agreement may be altered, amended or discharged only by the signed written agreement of the parties hereto.

 

[Remainder of Page Intentionally Left Blank]

 

	 
	
3

	

 

IN WITNESS WHEREOF, the parties hereto have executed this Independent Director Agreement as of the day and year first above written.

 

 

	
CELLCEUTIX CORPORATION, a Nevada corporation

	
DIRECTOR:

		  		 	 	
	 	 			
	
 

			
  

		
	
By:

	
 

		
By:

	
 

	
	
Name:

	
Leo Ehrlich

	
 

		 	
	
Title:

	
Chief Executive Officer

	
 

		 	

 

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}]]